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ORIGINAL ARTICLE – GASTROINTESTINAL ONCOLOGY
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ABSTRACT
Background. In a Dutch phase II trial conducted between
2006 and 2010, short-course radiotherapy followed by
systemic therapy with capecitabine, oxaliplatin, and beva-
cizumab as neoadjuvant treatment and subsequent radical
surgical treatment of primary tumor and metastatic sites
was evaluated. In this study, we report the long-term results
after a minimum follow-up of 6 years.
Methods. Patients with histologically confirmed rectal
adenocarcinoma with potentially resectable or ablat-
able metastases in liver or lungs were eligible. Follow-up
data were collected for all patients enrolled in the trial.
Overall and recurrence-free survival were calculated using
the Kaplan–Meier method.
Results. Follow-up data were available for all 50 patients.
After a median follow-up time of 8.1 years (range 6.0–9.8),
16 patients (32.0%) were still alive and 14 (28%) were
disease-free. The median overall survival was 3.8 years
(range 0.5–9.4). From the 36 patients who received radical
treatment, two (5.6%) had a local recurrence and 29
(80.6%) had a distant recurrence.
Conclusions. Long-term survival can be achieved in
patients with primary metastatic rectal cancer after
neoadjuvant radio- and chemotherapy. Despite a high
number of recurrences, 32% of patients were alive after a
median follow-up time of 8.1 years.
In approximately 20% of rectal cancer patients, the
tumor is already metastasized at first presentation.1,2 These
patients have a poor prognosis, with a life expectancy of
1 year after diagnosis.3 Presentation with synchronous
metastases creates a treatment dilemma: which tumor
location poses the biggest threat, and should treatment
initially be directed towards the primary tumor or the dis-
tant metastases.
In rectal cancer with synchronous metastases, the pri-
mary tumor has usually already progressed to a more
locally advanced stage (T3 or T4 according to the Ameri-
can Joint Committee on Cancer [AJCC] staging system),
with or without involvement of locoregional lymph nodes.
Advanced primary tumors require downstaging to enable
resection with adequate margins. Downstaging can be
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accomplished with neoadjuvant radiotherapy or chemora-
diotherapy.4,5 Long-course radiotherapy with concomitant
5-fluorouracil-based chemotherapy is the standard neoad-
juvant regimen for locally advanced rectal cancer.5 In
patients with synchronously metastasized rectal cancer, this
neoadjuvant scheme creates a long interval between the
start of treatment and surgery during which distant
metastases may progress. Furthermore, 5-fluorouracil, or
its oral analog capecitabine, acts as a radiosensitizer and
has no or little effect on distant metastases.
In a Dutch trial, known in The Netherlands as the M1 study, a
new chemoradiotherapy regimen was proposed for patients
with rectal cancer and synchronous metastases.6 In this study,
patients were treated with a short-course of radiotherapy
(5 9 5 Gy), followed by chemotherapy that consisted of a
combination of capecitabine, oxaliplatin and bevacizumab, and
eventually followed by radical treatment of all tumor sites. In
this regimen, short-course radiotherapy is administered to
achieve control of the primary tumor, while systemic treatment
with capecitabine and oxaliplatin (CapeOx) in combination
with bevacizumab is administrated as treatment for metastatic
disease.7,8 In 72% of participants, radical treatment of both
metastases and the primary tumor could be performed. In the
initial analysis, patients had been followed for at least 2 years.
The aim of this update is to study the impact of the study
treatment on long-term survival and recurrence of disease.
MATERIALS AND METHODS
Study Design
Full details of the design, patients’ eligibility criteria,
and procedures have been reported previously.6 In brief,
this study is an open-label, phase II clinical study that is
registered with the Netherlands Trial Register (NTR2029).
Between April 2006 and December 2010, 50 patients were
included in seven centers in The Netherlands. The primary
endpoint of the initial study was the percentage of patients
receiving radical treatment of all tumor sites. As secondary
endpoints, 2-year survival, 2-year local and distant recur-
rence rate and treatment-related toxicity were assessed.
Eligibility
Patients were eligible for this study if they were diag-
nosed with primary metastasized rectal cancer and were at
least 18 years of age. Rectal adenocarcinoma should be
histologically confirmed, and liver or lung metastases
should be eligible for resection or radiofrequency ablation
(RFA). The Institutional Review Board at each participat-
ing center approved the study protocol, and all patients
provided written informed consent.
Treatment and Study-Related Procedures
Treatment and procedures have been described previ-
ously.6 In summary, preoperative treatment started with
external beam radiotherapy (5 9 5 Gy) on the mesorectum
and regional lymph nodes. The upper field border was set at
L5/S1. Within 2 weeks after completion of radiotherapy,
chemotherapy started with six cycles of 3 weeks, consist-
ing of capecitabine-oxaliplatin-bevacizumab. On the first
day of a chemotherapy cycle, patients received beva-
cizumab (7.5 mg/kg) and oxaliplatin (130 mg/m2), both as
an intravenous infusion. During the first 2 weeks of each
cycle, capecitabine (1000 mg/m2) was administered as an
oral drug. Surgery was planned 6–8 weeks after the last
dose of bevacizumab, and the surgical treatment strategy
was personalized for each patient by a multidisciplinary
team. Radical treatment (R0) of the liver metastases was
defined as microscopic tumor-free resection margins or an
ablation zone completely covering the metastasis, includ-
ing a C5 mm peritumoral margin on the 1-week post-RFA
computed tomography (CT) scan.
Baseline imaging of the primary tumor was performed
with a pelvic contrast-enhanced CT or magnetic resonance
imaging (MRI), and, for imaging of distant metastases, a
CT scan of the chest and abdomen was used. Radiologic
response evaluation was performed after two cycles of
chemotherapy using a CT scan. If no progression of disease
was seen on the CT scan, patients additionally received
four cycles of chemotherapy. After completion of preop-
erative treatment, resectability of both the primary tumor
and metastases were reassessed using the same imaging
procedures as were used at baseline.
Histopathologic evaluation of the resection specimens
was performed by a pathologist following local standards,
and pathologic response after neoadjuvant therapy was
assessed using Mandard’s classification.9
Survival Follow-Up and Statistics
Follow-up visits as part of the study were carried out
every 3 months during the first 3 years. Thereafter, follow-
up was at the physician’s discretion. Overall and recur-
rence-free survival were calculated using the Kaplan–Meier
survival analysis method, with overall survival being
defined as the time from the start of radiotherapy until death
from any cause. Recurrence-free survival was calculated for
all patients in whom radical surgery was possible, with
recurrence-free survival being defined as the time from
radical surgery (after which the patient was rendered dis-
ease-free) to the diagnosis of first recurrence. The log-rank
test was used to compare the survival distribution of sub-
groups. All statistical analyses were performed using SPSS
(Released 2013. IBM SPSS Statistics for Windows, Version
Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin… 2633
22.0; IBM Corporation, Armonk, NY, USA), and a p value
of B0.05 was regarded as statistically significant.
RESULTS
Patient Characteristics
Follow-up data were available for all 50 patients. Patient
and treatment characteristics are described in Table 1.
Median follow-up duration was 8.1 years (range 6.0–9.8).
Thirty-six patients in the study received radical treatment
(R0), 10 patients had irresectable disease after neoadjuvant
radio- and chemotherapy, and in 4 patients the resection of
the primary rectal tumor was not radical (R1). Eleven of
the 43 patients (25.6%) who received a resection of the
primary rectal tumor, showed a pathological complete
response, and seven patients (16.3%) showed a pathologi-
cal near-complete response of the primary tumor.
Overall Survival
Median overall survival of the total cohort was 3.8 years
(range 0.5–9.4) (Fig. 1a). The overall survival rate after
2 years of treatment was 74% (37 of 50 patients). The
5-year survival rate was 38.0% (19 of 50 patients), and,
after a median follow-up time of 8.1 years, 32.0% (16 of 50
patients) of patients were alive. Fourteen of these 16
patients (28%) were disease-free after 8.1 years of follow-
up. In 36 of 50 patients, in whom radical (R0) treatment of
primary tumor and metastatic sites was achieved, median
overall survival was 4.4 years (Fig. 1b). Survival of these
patients was significantly better than in patients in whom
treatment was not radical (median overall survival
2.8 years; log-rank test p = 0.004).
Recurrence Rate
Of the 36 patients who received radical treatment, 29
(80.6%) had recurrence of the disease, with most of these
recurrences being distant metastases. Only two patients
developed a local recurrence, one in combination with a
distant recurrence. Both patients with a local recurrence
had a pathological partial response of the initial primary
tumor. The number and location of recurrences are pro-
vided in Table 2. The 2- and 5-year recurrence rates were
72.2 and 80.6%, respectively. Patients with recurrence of
metastatic disease had a median number of two metastases
at presentation with recurrent disease. One of the patients
with a local recurrence and 18 of 28 patients (64.3%) with
a distant recurrence could be rendered disease-free after
successful treatment of the recurrence. Treatment of the
distant recurrences consisted of surgery (11), RFA of liver
metastases (4), and stereotactic radiosurgery (3). Fourteen
of these 18 patients (77.8%) developed a second recur-
rence. Median recurrence-free survival, calculated after the
completion of treatment in this trial, was 7.4 months
(Fig. 2a). Median time to recurrence was 7.1 months.
Median recurrence-free survival for subgroups with or
without pathological complete response was 16.2 vs.
6.6 months, and the difference between the groups was
statistically significant (log-rank test p = 0.039) (Fig. 2b).
Overall and recurrence-free survival of all individual
patients are illustrated in a swimmers plot (Fig. 3).
TABLE 1 Patient and tumor characteristics
Characteristics Results
[N = 50]
Age at start of treatment, years [median (range)] 59 (35–75)



















Patients completing radiotherapy 50 (100)
Interval between completion of RT and start of CT—days
Median (range) 11 (3–44)
Chemotherapy
Patients receiving six cycles 42 (84)
Surgery
Radical surgical treatment 36 (72)
Sequence of surgery
Simultaneous resection 25 (50.0)
Primary first 10 (20)
Metastases first 5 (10)
Data are expressed as n (%) unless otherwise specified
RT radiotherapy, CT chemotherapy
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DISCUSSION
Long-term follow-up of patients in this trial showed that
long-term survival can be achieved in patients with primary
metastatic rectal cancer with a treatment regimen consist-
ing of neoadjuvant radio- and chemotherapy followed by
surgical resection of both the primary tumor and metastatic
sites. Thirty-two percent of patients were alive after a
median follow-up of 8.1 years, and 28% of patients were
disease-free at that time.
The number of long-term survivors in this trial can be
considered high, regarding the poor prognostic features of
the study population. For example, synchronous occurrence
of distant metastases and an advance stage of the primary
tumor are known as poor prognostic features in colorectal
cancer.10 In addition, patients with metastases in multiple
organs, who were eligible for this study, have a worse
progression-free survival.11 The median overall survival of
3.8 years is longer than could be expected in patients with
primary stage IV rectal cancer,4 but is in accordance with
other studies investigating neoadjuvant treatment before
surgical resection of all tumor sites;12–15 however, these
studies had a retrospective design and only included
patients with liver metastases.
Despite the high number of long-term survivors, many
radically treated patients experienced recurrence of disease
(80.6%). Distant recurrences were mainly seen, which is
known as the preferred pattern of recurrence in primary
metastatic rectal cancer.16 Most of the recurrences occurred
shortly after study treatment; 21 of 29 (72.4%) recurrences
occurred within 1 year. The high early recurrence rate
could be the result of missed (micro-) metastases by CT
scan, which was the only mandatory method of radiological
evaluation in this trial. Particularly in relation to the
detection of extrahepatic tumor recurrences, which were
seen in 20 of 36 (55.6%) patients who received radical
treatment in this study, a combined positron emission
tomography (PET)-CT scan outperformed a conventional
CT scan.17,18 Because PET-CT could detect extrahepatic
tumor sites at an earlier stage, a more radical treatment of
all tumor locations could be performed to prevent recur-
rences. The high recurrence rate had no significant effect
on survival, which may be explained by the fact that many
patients could be treated with curative intent for their
recurrence. Repeat treatments of recurrent colorectal
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FIG. 1 Overall survival (months) in a the total study population (N = 50) and b subgroups that did (N = 36) and did not (N = 14) receive
radical treatment of primary tumor and/or distant metastases
TABLE 2 Anatomic location of recurrences of rectal cancer in
patients receiving radical treatment (N = 36)
Anatomic location Frequency Percentage
Rectum (local) 2 5.6
Liver 10 27.8
Lung 9 25.0
Liver and lung 3 8.3
Liver, lung, and lymph nodes 2 5.6
Other 4 11.1
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metastases is possible in approximately 50% of patients,
and contributes to a prolonged survival.19 The high and
early recurrence rate in our study is in accordance with
other studies.12,16
The aim of the chemotherapy regimen in this study was to
achieve both local control of the primary rectal tumor and
adequate treatment of distant metastases. Therefore short-
course radiotherapy (5 9 5 Gy) was followed by adequate
systemic cycles of capecitabine, oxaliplatin and beva-
cizumab. Systemic chemotherapy is capable of downsizing
metastatic lesions and can convert unresectable or borderline
resectable metastases into resectable metastases.20,21 The
high number of pathological complete (25.6%) or near-
complete (16.3%) responses and low local recurrence rate
(5.6%) in this study indicates local control can be achieved
with the regimen used in this study. A study in patients with
symptomatic primary rectal tumors and unresectable distant
metastases showed that short-course radiotherapy and
oxaliplatin-based chemotherapy can achieve local control,
even in patients with near-obstructing primary tumors.22,23
This treatment regimen led to a favorable palliative effect in
nearly two-thirds of patients, and palliative surgery was
needed in only 20% of patients. An important predictor for
pathological response of the primary tumor is the time
between radiotherapy and surgery, a longer interval being
associated with a higher rate of pathological response.24 In
this study, an interval of approximately 25 weeks existed
between short-course radiotherapy and surgery in patients
receiving all six cycles of chemotherapy, which could
explain the high pathological response rate.
Timing and sequence of surgical resection of a pri-
mary tumor with metastatic sites is still subject to debate;
surgical treatment could be directed at the primary tumor
first, at the metastases first (liver-first approach), or both
primary tumor and metastases could be treated simulta-
neously. Because resection of the primary tumor has no
impact on overall survival as opposed to resection of the
metastasis, and the metastases can potentially give rise to
further systemic spread of the disease, the latter should
not be delayed and a metastasis-first or simultaneous
approach are preferable.13,15 Furthermore, the complica-
tion rate of a simultaneous resection is not inferior to a
staged resection, but total hospital stay is significantly
shorter.12,25 Both resection of the primary rectal tumor
and resection of hepatic or extrahepatic rectal cancer
metastases can cause significant morbidity;26,27 therefore,
radiological restaging after neoadjuvant therapy is
important to make sure that all tumor locations are still
resectable. A simultaneous resection of primary tumor
and distant metastases was pursued in this study,
although in 15 patients this was not feasible and a staged
resection was performed.
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FIG. 2 Recurrence-free survival (months) for a patients who received surgical treatment of all tumor sites (N = 40) and b subgroups with
(N = 11) or without (N = 29) pathological complete response after surgical treatment in the study. CR complete response
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CONCLUSIONS
We showed that long-term survival, as well as local
control of the rectal tumor, can be achieved in patients
presenting with rectal cancer and synchronous metastases in
liver or lungs by preoperative treatment with short-course
radiotherapy and chemotherapy with capecitabine, oxali-
platin and bevacizumab, followed by radical treatment.
Patients should be carefully selected by a multidisciplinary
team for this treatment strategy, and resectability of all
tumor locations should be properly assessed at the start of
treatment and reassessed after completion of neoadjuvant
treatment.
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